GHK-Cu vs AOD-9604
Both compounds have been investigated for tissue-related endpoints, but in different tissues and through unrelated mechanisms. GHK-Cu has been studied for copper-mediated skin remodeling and antioxidant chemistry. AOD-9604 has been studied for lipolytic activity as a growth-hormone fragment. This page summarises how the published research separates them.
Side-by-side comparison
| Property | Compound A | Compound B |
|---|---|---|
| Structural class | Tripeptide-copper(II) complex (Gly-His-Lys-Cu2+) | Modified C-terminal fragment (AA 177-191) of human growth hormone |
| Approximate molecular weight | 402.91 g/mol | 1815.1 g/mol |
| Best-studied mechanism | Copper-mediated antioxidant chemistry; MMP/collagen modulation in dermal fibroblasts | Proposed lipolytic activity via incompletely characterised pathway; no GH receptor binding |
| Primary tissues | Dermal fibroblast, keratinocyte, hair follicle, wound-bed ECM | Adipose tissue; more recently, intra-articular cartilage |
| Common research routes | Topical, subcutaneous | Subcutaneous, oral, intra-articular |
| Ronin catalog vial size | 50 mg lyophilised | 5 mg lyophilised |
How they differ in mechanism
GHK-Cu operates through copper-bound-tripeptide chemistry. The Cu2+ ion is integral to the active species. Published in-vitro and ex-vivo work reports quenching of reactive carbonyl species, modulation of integrin and p63 expression in keratinocytes, and altered MMP and collagen expression in dermal fibroblasts. Gene-expression profiling by Pickart and colleagues describes broad transcriptomic effects relevant to skin regeneration.
AOD-9604 is a modified growth-hormone C-terminal fragment studied for lipolytic and fat-oxidation activity. The compound does not bind the GH receptor, and the signalling pathway mediating its effects is incompletely characterised. The Heffernan studies demonstrated weight loss and fat oxidation in obese mice. More recent work has examined AOD-9604 in intra-articular injection for osteoarthritis.
The two compounds are mechanistically unrelated. GHK-Cu acts through copper-mediated redox chemistry and matrix remodeling in skin. AOD-9604 acts through an undefined lipolytic pathway in adipose tissue. The tissues, mechanisms, and research communities do not overlap.
How research has examined each
The GHK-Cu literature spans decades of work on skin-remodeling biology, oxidative-stress chemistry, keratinocyte signalling, and dermal-fibroblast collagen dynamics. Recent work has extended to lung-fibrosis and zebrafish-inflammation models.
The AOD-9604 literature centres on rodent adipose-tissue pharmacology from the early 2000s, with more recent work on intra-articular injection for osteoarthritis endpoints. The compound did not advance through large-scale clinical development for metabolic indications.
The two literatures do not intersect. GHK-Cu is read by dermatology and cosmetic-science researchers. AOD-9604 is read by metabolic-peptide and orthopaedic researchers.
Stacking considerations in research contexts
Combined administration is not described in published research. The mechanisms and tissues are unrelated. Both compounds are available at their standard vial sizes (GHK-Cu at 50 mg, AOD-9604 at 5 mg) in the Ronin catalog.
Sourcing both at Ronin
Both compounds ship as lyophilised material in glass vials with certificate-of-analysis documentation. The GHK-Cu vial page ships at 50 mg. The AOD-9604 vial page ships at 5 mg. Both are research-grade reagents.
Frequently asked research questions
Are GHK-Cu and AOD-9604 related?
No. GHK-Cu is a copper-bound tripeptide for skin-remodeling research. AOD-9604 is a GH fragment for fat-metabolism research. Different targets and tissues.
Do they share any research domain?
Only at the broadest ‘research peptide’ level. GHK-Cu work is in dermatology; AOD-9604 work is in adipose-tissue pharmacology.
Are they co-administered?
Not in published research.
Do they share storage practice?
Yes. Both are lyophilised, stored at 2-8 degrees Celsius.
Are either approved?
Neither is FDA or Health Canada approved. Both are research-grade reagents.
References
- Heffernan MA et al. Increase of fat oxidation and weight loss in obese mice caused by human growth hormone or a modified C-terminal fragment. International Journal of Obesity, 2001. [PMID 11673763]
- Pickart L. The human tri-peptide GHK and tissue remodeling. Journal of Biomaterials Science Polymer Edition, 2008. [PMID 18644225]
- Pickart L et al. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International, 2015. [PMID 26236730]
- Kwon DR et al. Effect of intra-articular injection of AOD9604 in rabbit osteoarthritis model. Annals of Clinical and Laboratory Science, 2015. [PMID 26275694]
- Pickart L et al. Regenerative and Protective Actions of the GHK-Cu Peptide. International Journal of Molecular Sciences, 2018. [PMID 29986520]
Comparison pages describe research-context use of the compared compounds. They do not constitute medical, veterinary, or clinical advice. Every compound in the Ronin catalog is sold strictly for laboratory and research use only.